Navigation Links
FDA Renews its Contract with Beaumont Technology Usability Center for Leadership of Patient Safety Project
Date:2/1/2008

ROYAL OAK, Mich., Feb. 1 /PRNewswire/ -- The Beaumont Technology Usability Center will begin research on the next phase of the U.S. Food and Drug Administration's study on tubing and catheter misconnection errors.

In 2006, the Joint Commission released a Sentinel Event Alert on the potential dangers of tubing misconnections. According to the Alert, eight deaths and one instance of permanent loss of function were due to tubing misconnections. It also stated that "misconnection errors occur with significant frequency and, in a number of instances, lead to deadly consequences." Many of the medical devices used to deliver medication and gases to patients have similar or even identical connectors. Research is being conducted industry-wide to ensure a safer connector design.

In December 2006, the U.S. Food and Drug Administration (FDA) and Social and Scientific Systems, Inc., under the support of FDA's Medical Product Safety Network (MedSun), contracted with the Beaumont Technology Usability Center (BTUC). BTUC developed an innovative risk assessment approach with several educational tools intended to increase awareness of healthcare professionals and provide strategies to reduce patient risk.

Today, the FDA asked BTUC to continue contributing to their nationwide initiative. BTUC clinical engineers and clinicians with the Department of Education at Beaumont Hospital, Troy, will use the new approach to examine the types of connectors that are currently in use and the potential risk associated with each setup.

"We are excited to provide results that will be used to define the next steps in this nationwide problem. By helping the FDA increase awareness, the entire healthcare community can work together to create a safer clinical environment," said Izabella Gieras, BTUC's Director of Technology Management.

About the Beaumont Technology Usability Center

The Beaumont Technology Usability Center's mission is to advance excellence in healthcare by improving medical technology and its use. The Usability Center provides medical device and equipment manufacturers with product development services that improve patient safety, minimize the cost of product development, and shorten the time-to-market.

The Usability Center's multidisciplinary team of human factors engineers, clinical technology engineers, and patient care specialists are affiliated with Beaumont Hospitals, comprised of a 1,061-bed major academic, research, and referral center in Royal Oak, MI; a 346-bed acute care community teaching hospital in Troy, MI; and a 289-bed community hospital in Grosse Pointe, MI; along with multiple specialty care centers throughout the community. For more information, please see http://www.beaumontusability.com .

Steve Ebben

Vice President

Planning & Marketing

248.551.2667

steve.ebben@beaumontservices.com


'/>"/>
SOURCE Beaumont Technology Usability Center
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ABQAURP Renews Agreement with the National Board of Medical Examiners to Oversee Testing Methodology
2. Heart Association Renews Call for CPR Training
3. FDA Renews Warnings on Pain-Relief Patch
4. Acclamation Systems, Inc. Renews Partnership with Coalition America to Offer Streamlined Repricing and Adjudication Solution
5. Independence Technology, A Johnson & Johnson Company, Renews Its Contract With Creative Technology Services
6. Sanofi-Aventis renews licenses for Genomatix chip analysis pipeline
7. NIH/NCI renews and extends nationwide license for Genomatix software and databases
8. Coalition America Renews Relationship with Musketeer to Offer Streamlined Claims Repricing and Adjudication Solution for Benefit Administrators
9. Wacoal Renews Successful Support the Girls Program
10. Perdue AgriBusiness Announces Low Linolenic Soybean Contracting Opportunities with DuPont Business Pioneer Hi-Bred
11. Cardiac Science Wins Major Corporate AED Deployment Contracts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2017)... ... 2017 , ... “Childhood Memories of a Virginia Wanderer”: an entertaining look ... relive their own youth. “Childhood Memories of a Virginia Wanderer” is the creation of ... nine years. He received his BS from Idaho State University in Adult Education, ...
(Date:9/26/2017)... ... , ... “The Tour Guide”: is the life story of the author and the exciting times ... Alexander Stark, is an adventure tour guide and the subject of the book. , ... confront fifteen shocked faces. I played it off as a part of the adventure tour, ...
(Date:9/26/2017)... ... , ... “The Great Creator Saves Boobie and Ceebie”: a tool families can use to teach ... the creation of published author, G.S. White, a devoted follower of Jesus Chris who is ... , “This book is not only for children but also to glorified God in everything ...
(Date:9/25/2017)... CA (PRWEB) , ... September 26, 2017 , ... Your ... agent in February 2017 and began fulfilling a life-long wish of owner Stacy Boyle ... “I was a recipient of help when I was in high school,” said Ms. ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... and only fully programmable fall detection smart watch. VitalBand provides elite level ... contacts as you want so help arrives quickly. Plus, it’s a fully ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
Breaking Medicine Technology: